{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:25:51Z","timestamp":1790249151924,"version":"4.1.0"},"reference-count":172,"publisher":"Bioscientifica","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["erc.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:p>The management of cancer patients has changed due to the considerably more frequent use of immune checkpoint inhibitors (ICPIs). However, the use of ICPI has a risk of side effects, particularly endocrine toxicity. Since the indications for ICPI are constantly expanding due to their efficacy, it is important that endocrinologists and oncologists know how to look for this type of toxicity and how to treat it when it arises. In view of this, the French Endocrine Society initiated the formulation of a consensus document on ICPI-related endocrine toxicity. In this paper, we will introduce data on the general pathophysiology of endocrine toxicity, and we will then outline expert opinion focusing primarily on methods for screening, management and monitoring for endocrine side effects in patients treated by ICPI. We will then look in turn at endocrinopathies that are induced by ICPI including dysthyroidism, hypophysitis, primary adrenal insufficiency and fulminant diabetes. In each chapter, expert opinion will be given on the diagnosis, management and monitoring for each complication. These expert opinions will also discuss the methodology for categorizing these side effects in oncology using \u2018common terminology criteria for adverse events\u2019 (CTCAE) and the difficulties in applying this to endocrine side effects in the case of these anti-cancer therapies. This is shown in particular by certain recommendations that are used for other side effects (high-dose corticosteroids, contraindicated in ICPI for example) and that cannot be considered as appropriate in the management of endocrine toxicity, as it usually does not require ICPI withdrawal or high-dose glucocorticoid intake.<\/jats:p>","DOI":"10.1530\/erc-18-0320","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T11:06:17Z","timestamp":1539083177000},"page":"G1-G18","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":126,"title":["French Endocrine Society Guidance on endocrine side effects of immunotherapy"],"prefix":"10.1530","volume":"26","author":[{"given":"F","family":"Castinetti","sequence":"first","affiliation":[{"name":"1Aix-Marseille Universit\u00e9, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), U1251, Marseille Medical Genetics (MMG), and Department of Endocrinology, Assistance Publique-H\u00f4pitaux de Marseille (AP-HM), H\u00f4pital de la Conception, Centre de R\u00e9f\u00e9rence des Maladies Rares de l\u2019Hypophyse HYPO, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Albarel","sequence":"additional","affiliation":[{"name":"1Aix-Marseille Universit\u00e9, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), U1251, Marseille Medical Genetics (MMG), and Department of Endocrinology, Assistance Publique-H\u00f4pitaux de Marseille (AP-HM), H\u00f4pital de la Conception, Centre de R\u00e9f\u00e9rence des Maladies Rares de l\u2019Hypophyse HYPO, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Archambeaud","sequence":"additional","affiliation":[{"name":"2Service de M\u00e9decine Interne B \u2013 Endocrinologie, Limoges Cedex, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Bertherat","sequence":"additional","affiliation":[{"name":"3H\u00f4pital Cochin, Service d\u2019Endocrinologie et Maladies M\u00e9taboliques, Paris Cedex 14, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Bouillet","sequence":"additional","affiliation":[{"name":"4CHU Dijon, H\u00f4pital Fran\u00e7ois Mitterrand, Service d\u2019Endocrinologie, Diab\u00e9tologie, Maladies M\u00e9taboliques, Dijon Cedex, France"},{"name":"5Unit\u00e9 INSERM LNC-UMR 1231, Universit\u00e9 de Bourgogne, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Buffier","sequence":"additional","affiliation":[{"name":"4CHU Dijon, H\u00f4pital Fran\u00e7ois Mitterrand, Service d\u2019Endocrinologie, Diab\u00e9tologie, Maladies M\u00e9taboliques, Dijon Cedex, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Briet","sequence":"additional","affiliation":[{"name":"6Institut MITOVASC, INSERM U1083, Angers University, Department of Endocrinology, Diabetology and Nutrition, University Medical Center, Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Cariou","sequence":"additional","affiliation":[{"name":"7Department of Endocrinology, L\u2019Institut du Thorax, CHU Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ph","family":"Caron","sequence":"additional","affiliation":[{"name":"8CHU de Toulouse \u2013 H\u00f4pital Larrey \u2013 Service d\u2019Endocrinologie \u2013 Maladies m\u00e9taboliques \u2013 Nutrition, TSA 30030, Toulouse Cedex 9, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Chabre","sequence":"additional","affiliation":[{"name":"9CHU de Grenoble \u2013 H\u00f4pital Albert Michallon, Service d\u2019Endocrinologie-Diab\u00e9tologie-Nutrition, Grenoble Cedex 9, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ph","family":"Chanson","sequence":"additional","affiliation":[{"name":"10Assistance Publique-H\u00f4pitaux de Paris (AP-HP), H\u00f4pital de Bic\u00eatre, Service d\u2019Endocrinologie et des Maladies de la Reproduction, et UMR S-1185 Facult\u00e9 de M\u00e9decine Paris-Sud, University of Paris-Saclay, Le Kremlin-Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Cortet","sequence":"additional","affiliation":[{"name":"11CHRU de Lille \u2013 Hopital Huriez, Service d\u2019Endocrinologie, Lille Cedex, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Do Cao","sequence":"additional","affiliation":[{"name":"11CHRU de Lille \u2013 Hopital Huriez, Service d\u2019Endocrinologie, Lille Cedex, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Drui","sequence":"additional","affiliation":[{"name":"7Department of Endocrinology, L\u2019Institut du Thorax, CHU Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Haissaguerre","sequence":"additional","affiliation":[{"name":"12CHU de Bordeaux \u2013 H\u00f4pital du Haut L\u00e9v\u00eaque, Service d\u2019Endocrinologie-Diab\u00e9tologie et Maladies M\u00e9taboliques, Pessac Cedex, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Hescot","sequence":"additional","affiliation":[{"name":"13Institut Curie, Oncologie Endocrinienne, Saint Cloud, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Illouz","sequence":"additional","affiliation":[{"name":"14Department of Endocrinology, Diabetes and Nutrition, Reference Centre of Rare Thyroid Disease, Hospital of Angers, Angers Cedex 09, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Kuhn","sequence":"additional","affiliation":[{"name":"10Assistance Publique-H\u00f4pitaux de Paris (AP-HP), H\u00f4pital de Bic\u00eatre, Service d\u2019Endocrinologie et des Maladies de la Reproduction, et UMR S-1185 Facult\u00e9 de M\u00e9decine Paris-Sud, University of Paris-Saclay, Le Kremlin-Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Lahlou","sequence":"additional","affiliation":[{"name":"15D\u00e9partement d\u2019Hormonologie Sp\u00e9cialis\u00e9e, BPR-AS, Pannes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Merlen","sequence":"additional","affiliation":[{"name":"11CHRU de Lille \u2013 Hopital Huriez, Service d\u2019Endocrinologie, Lille Cedex, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Raverot","sequence":"additional","affiliation":[{"name":"16Hospices Civils de Lyon, Laboratoire d\u2019Hormonologie, Service de Biochimie et Biologie Mol\u00e9culaire, Groupement Hospitalier Est, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Smati","sequence":"additional","affiliation":[{"name":"7Department of Endocrinology, L\u2019Institut du Thorax, CHU Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Verges","sequence":"additional","affiliation":[{"name":"4CHU Dijon, H\u00f4pital Fran\u00e7ois Mitterrand, Service d\u2019Endocrinologie, Diab\u00e9tologie, Maladies M\u00e9taboliques, Dijon Cedex, France"},{"name":"5Unit\u00e9 INSERM LNC-UMR 1231, Universit\u00e9 de Bourgogne, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Borson-Chazot","sequence":"additional","affiliation":[{"name":"17Hospices Civils de Lyon, F\u00e9d\u00e9ration d\u2019Endocrinologie, Universit\u00e9 Claude Bernard Lyon 1, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"ref1541","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1073\/pnas.1417320112","article-title":"Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients","volume":"112","year":"2015","journal-title":"PNAS"},{"key":"ref1601","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","year":"2018","journal-title":"Diabetes"},{"key":"ref1031","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","year":"2016","journal-title":"Annals of Oncology"},{"key":"ref1551","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","year":"2014","journal-title":"Endocrine-Related Cancer"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab","volume":"101","year":"2016","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1661","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"ref861","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-14-0845","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma","volume":"172","year":"2015","journal-title":"European Journal of Endocrinology"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","year":"2014","journal-title":"Lancet Oncology"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"ref961","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000485742","article-title":"Severe inflammatory ophthalmopathy in a euthyroid patient during nivolumab treatment","volume":"7","year":"2018","journal-title":"European Thyroid Journal"},{"key":"ref291","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/annonc\/mdx225","article-title":"Guidelines Committee Management of toxicities from immunotherapy Practice Guidelines for diagnosis treatment and follow - up of iv iv https org","volume":"28","author":"ESMO","year":"2017","journal-title":"Clinical Annals Oncology"},{"key":"ref1351","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1479-5876-11-108","article-title":"The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-\u03b1 production","volume":"11","year":"2013","journal-title":"Journal of Translational Medicine"},{"key":"ref1051","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1530\/ERC-17-0358","article-title":"CukierPSantiniFCScarantiMHoffAO side effects of cancer immunotherapy - Related https org","volume":"24","year":"2017","journal-title":"Endocrine Endocrine Cancer"},{"key":"ref1081","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes","volume":"13","year":"2010","journal-title":"Pituitary"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series","volume":"186","year":"2016","journal-title":"American Journal of Pathology"},{"key":"ref1571","first-page":"175","article-title":"The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma","volume":"178","year":"2018","journal-title":"European Journal of Endocrinology"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1479-5876-11-108","article-title":"The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-\u03b1 production","volume":"11","year":"2013","journal-title":"Journal of Translational Medicine"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","year":"2017","journal-title":"Annals of Oncology"},{"key":"ref1221","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","year":"2016","journal-title":"Lancet Oncology"},{"key":"ref911","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1600-065X.2011.01011.x","article-title":"Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28\/\u200aB7 family","volume":"241","year":"2011","journal-title":"Immunological Reviews"},{"key":"ref1581","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy","volume":"350","year":"2015","journal-title":"Science"},{"key":"ref1671","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(16)30126-7","article-title":"Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial","volume":"17","year":"2016","journal-title":"Lancet Oncology"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","year":"2014","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref821","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"ref1651","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1200\/JCO.2008.16.1927","article-title":"Phase I\/II study of ipilimumab for patients with metastatic melanoma","volume":"26","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine side effects induced by immune checkpoint inhibitors","volume":"98","year":"2013","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1091","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade","volume":"13","year":"2007","journal-title":"Clinical Cancer Research"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","year":"2016","journal-title":"Cancer Treatment Reviews"},{"key":"ref1151","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/annonc\/mdx225","article-title":"Guidelines Committee Management of toxicities from immunotherapy Practice Guidelines for diagnosis treatment and follow - up of iv iv https org","volume":"28","author":"ESMO","year":"2017","journal-title":"Clinical Annals Oncology"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2005.01.001","article-title":"Immunogenicity of engineered antibodies","volume":"36","year":"2005","journal-title":"Methods"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1530\/EJE-10-0833","article-title":"Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy","volume":"164","year":"2011","journal-title":"European Journal of Endocrinology"},{"key":"ref1561","first-page":"253","article-title":"New advances in therapeutic use of monoclonal antibodies","volume-title":"Revue Medicale de Liege","volume":"64","year":"2009"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/cam4.1145","article-title":"Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists","volume":"6","year":"2017","journal-title":"Cancer Medicine"},{"key":"ref921","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ando.2018.07.008","article-title":"Expert opinion on pituitary complications in immunotherapy.","volume":"79","year":"2018","journal-title":"Annales d\u2019Endocrinologie"},{"key":"ref1381","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/pbc.25508","article-title":"Tumor-targeted and immune-targeted monoclonal antibodies: going from passive to active immunotherapy","volume":"62","year":"2015","journal-title":"Pediatric Blood and Cancer"},{"key":"ref971","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/MED.0b013e32835430ed","article-title":"Update on the diagnosis and management of hypophysitis","volume":"19","year":"2012","journal-title":"Current Opinion in Endocrinology, Diabetes, and Obesity"},{"key":"ref1441","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study","volume":"21","year":"2015","journal-title":"Clinical Cancer Research"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ando.2018.07.001","article-title":"Introduction to expert opinion on endocrine complications of new anti-cancer therapies.","volume":"79","year":"2018","journal-title":"Annales d\u2019Endocrinologie"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/cen.13297","article-title":"Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma","volume":"86","year":"2017","journal-title":"Clinical Endocrinology"},{"key":"ref891","first-page":"173","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","year":"2017","journal-title":"JAMA Oncology"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1055\/s-0033-1355337","article-title":"Hypophysitis caused by ipilimumab in cancer patients: hormone replacement or immunosuppressive therapy","volume":"121","year":"2013","journal-title":"Experimental and Clinical Endocrinology and Diabetes"},{"key":"ref1071","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms","volume":"102","year":"2017","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ando.2018.07.008","article-title":"Expert opinion on pituitary complications in immunotherapy.","volume":"79","year":"2018","journal-title":"Annales d\u2019Endocrinologie"},{"key":"ref1211","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"ref881","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1097\/RLU.0000000000000887","article-title":"induced adrenalitis a possible pitfall in PET https org","volume":"18","author":"Ipilimumab","journal-title":"Clinical Nuclear Medicine"},{"key":"ref341","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EC-18-0068","article-title":"for Endocrinology Clinical Committee FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE : Acute management of the endocrine complications of checkpoint inhibitor therapy Connections https org","volume":"7","author":"HighamCEOlsson","year":"2018","journal-title":"Society SOCIETY Endocrine"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ando.2018.07.004","article-title":"Expert opinions on endocrine toxicity induced by new anticancer therapies: precautions to be taken in performing and interpreting hormonal assays under immunotherapy","volume":"79","year":"2018","journal-title":"Annales d\u2019Endocrinologie"},{"key":"ref1371","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1470-2045(12)70006-2","article-title":"Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial","volume":"13","year":"2012","journal-title":"Lancet Oncology"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","year":"2017","journal-title":"Annals of Oncology"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(16)30126-7","article-title":"Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial","volume":"17","year":"2016","journal-title":"Lancet Oncology"},{"key":"ref1201","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EC-18-0068","article-title":"for Endocrinology Clinical Committee FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE : Acute management of the endocrine complications of checkpoint inhibitor therapy Connections https org","volume":"7","author":"HighamCEOlsson","year":"2018","journal-title":"Society SOCIETY Endocrine"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1470-2045(12)70006-2","article-title":"Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial","volume":"13","year":"2012","journal-title":"Lancet Oncology"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"638","DOI":"10.2337\/dc17-2243","article-title":"Anti-programmed death 1 (PD-1) antibodies and the pancreas: a diabetic storm ahead?","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"ref1421","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2213-8587(13)70031-7","article-title":"Ipilimumab-induced autoimmune adrenalitis","volume":"1","year":"2013","journal-title":"Lancet Diabetes and Endocrinology"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review","volume":"85","year":"2016","journal-title":"Clinical Endocrinology"},{"key":"ref1701","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"ref1481","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","article-title":"Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial","volume":"19","year":"2018","journal-title":"Lancet Oncology"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/MED.0b013e32835430ed","article-title":"Update on the diagnosis and management of hypophysitis","volume":"19","year":"2012","journal-title":"Current Opinion in Endocrinology, Diabetes, and Obesity"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","article-title":"Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial","volume":"19","year":"2018","journal-title":"Lancet Oncology"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody.","volume":"6","year":"2014","journal-title":"Science Translational Medicine"},{"key":"ref871","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.20022125","article-title":"The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice","volume":"198","year":"2003","journal-title":"Journal of Experimental Medicine"},{"key":"ref1431","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1530\/EJE-10-0833","article-title":"Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy","volume":"164","year":"2011","journal-title":"European Journal of Endocrinology"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy \u2013 immune checkpoint blockade and associated endocrinopathies.","volume":"13","year":"2017","journal-title":"Nature Reviews Endocrinology"},{"key":"ref771","first-page":"16-0108","article-title":"Hyponatraemia secondary to nivolumab-induced primary adrenal failure","volume":"2016","year":"2016","journal-title":"Endocrinology, Diabetes and Metabolism Case Reports"},{"key":"ref1041","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine side effects induced by immune checkpoint inhibitors","volume":"98","year":"2013","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1161","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ando.2018.07.002","article-title":"Expert opinions on adrenal complications in immunotherapy","volume":"79","year":"2018","journal-title":"Annales d\u2019Endocrinologie"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"ref1401","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3109\/01676830.2014.949792","article-title":"Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab","volume":"33","year":"2014","journal-title":"Orbit"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2018.04.001","article-title":"Immunotherapy-induced Addison\u2019s disease: a rare, persistent and potentially lethal side-effect","volume":"97","year":"2018","journal-title":"European Journal of Cancer"},{"key":"ref1321","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ando.2018.07.004","article-title":"Expert opinions on endocrine toxicity induced by new anticancer therapies: precautions to be taken in performing and interpreting hormonal assays under immunotherapy","volume":"79","year":"2018","journal-title":"Annales d\u2019Endocrinologie"},{"key":"ref1621","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1530\/EJE-13-0434","article-title":"side - effects of anti - cancer drugs mAbs and pituitary dysfunction clinical evidence and pathogenic hypotheses of https org","year":"2013","journal-title":"Endocrine European Journal Endocrinology"},{"key":"ref701","first-page":"253","article-title":"New advances in therapeutic use of monoclonal antibodies","volume-title":"Revue Medicale de Liege","volume":"64","year":"2009"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ando.2018.07.002","article-title":"Expert opinions on adrenal complications in immunotherapy","volume":"79","year":"2018","journal-title":"Annales d\u2019Endocrinologie"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","year":"2015","journal-title":"Science"},{"key":"ref1311","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","year":"2014","journal-title":"Lancet Oncology"},{"key":"ref761","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1530\/EJE-13-0434","article-title":"side - effects of anti - cancer drugs mAbs and pituitary dysfunction clinical evidence and pathogenic hypotheses of https org","year":"2013","journal-title":"Endocrine European Journal Endocrinology"},{"key":"ref1121","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","year":"2014","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1521","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","year":"2015","journal-title":"Lancet Oncology"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade","volume":"13","year":"2007","journal-title":"Clinical Cancer Research"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.autrev.2008.04.016","article-title":"Pituitary autoimmunity: 30 years later","volume":"7","year":"2008","journal-title":"Autoimmunity Reviews"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","year":"2016","journal-title":"Annals of Oncology"},{"key":"ref951","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy \u2013 immune checkpoint blockade and associated endocrinopathies.","volume":"13","year":"2017","journal-title":"Nature Reviews Endocrinology"},{"key":"ref981","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ando.2018.07.001","article-title":"Introduction to expert opinion on endocrine complications of new anti-cancer therapies.","volume":"79","year":"2018","journal-title":"Annales d\u2019Endocrinologie"},{"key":"ref1131","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-3083.1989.tb01225.x","article-title":"The IgG subclass pattern of complement activation depends on epitope density and antibody and complement concentration","volume":"30","year":"1989","journal-title":"Scandinavian Journal of Immunology"},{"key":"ref1261","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody.","volume":"6","year":"2014","journal-title":"Science Translational Medicine"},{"key":"ref1111","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","year":"2016","journal-title":"Pituitary"},{"key":"ref1181","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10637-009-9376-8","article-title":"A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-na\u00efve patients with advanced melanoma","volume":"29","year":"2011","journal-title":"Investigational New Drugs"},{"key":"ref1291","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","year":"2017","journal-title":"Annals of Oncology"},{"key":"ref1461","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","year":"2017","journal-title":"Annals of Oncology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.20022125","article-title":"The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice","volume":"198","year":"2003","journal-title":"Journal of Experimental Medicine"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","year":"2015","journal-title":"Lancet Oncology"},{"key":"ref1241","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/cam4.1145","article-title":"Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists","volume":"6","year":"2017","journal-title":"Cancer Medicine"},{"key":"ref1281","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1084\/jem.20051776","article-title":"Tissue expression of PD-L1 mediates peripheral T cell tolerance","volume":"203","year":"2006","journal-title":"Journal of Experimental Medicine"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1073\/pnas.1417320112","article-title":"Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients","volume":"112","year":"2015","journal-title":"PNAS"},{"key":"ref1611","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","year":"2017","journal-title":"Cancer Treatment Reviews"},{"key":"ref711","first-page":"175","article-title":"The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma","volume":"178","year":"2018","journal-title":"European Journal of Endocrinology"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMc1509660","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ando.2017.10.007","article-title":"Group 4: replacement therapy for adrenal insufficiency","volume":"78","year":"2017","journal-title":"Annales d\u2019Endocrinologie"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ando.2018.07.007","article-title":"Expert opinion on thyroid complications in immunotherapy","volume":"79","year":"2018","journal-title":"Annales d\u2019Endocrinologie"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","year":"2015","journal-title":"Lancet Oncology"},{"key":"ref1021","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series","volume":"186","year":"2016","journal-title":"American Journal of Pathology"},{"key":"ref1471","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1210\/js.2017-00170","article-title":"Polyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma","volume":"1","year":"2017","journal-title":"Journal of the Endocrine Society"},{"key":"ref1511","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"ref1531","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","year":"2015","journal-title":"Lancet Oncology"},{"key":"ref1341","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMc1509660","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"ref1691","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"ref1001","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ando.2018.07.005","article-title":"Endocrine side-effects of new anticancer therapies: overall monitoring and conclusions","volume":"79","year":"2018","journal-title":"Annales d\u2019Endocrinologie"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"76565","DOI":"10.18632\/oncotarget.12088","article-title":"Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors","volume":"7","year":"2016","journal-title":"Oncotarget"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","year":"2018","journal-title":"Diabetes"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","year":"2017","journal-title":"Frontiers in Pharmacology"},{"key":"ref1451","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/cen.13297","article-title":"Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma","volume":"86","year":"2017","journal-title":"Clinical Endocrinology"},{"key":"ref1391","doi-asserted-by":"crossref","first-page":"638","DOI":"10.2337\/dc17-2243","article-title":"Anti-programmed death 1 (PD-1) antibodies and the pancreas: a diabetic storm ahead?","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"ref851","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","article-title":"Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis","volume":"30","year":"2007","journal-title":"Journal of Immunotherapy"},{"key":"ref901","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"ref931","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","article-title":"Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses","volume":"113","year":"2009","journal-title":"Blood"},{"key":"ref1711","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","article-title":"Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis","volume":"30","year":"2007","journal-title":"Journal of Immunotherapy"},{"key":"ref1681","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"ref191","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1530\/ERC-17-0358","article-title":"CukierPSantiniFCScarantiMHoffAO side effects of cancer immunotherapy - Related https org","volume":"24","year":"2017","journal-title":"Endocrine Endocrine Cancer"},{"key":"ref1101","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","year":"2016","journal-title":"Cancer Treatment Reviews"},{"key":"ref631","first-page":"1165","article-title":"Adverse events associated with immune checkpoint blockade","volume":"378","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"ref31","first-page":"173","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","year":"2017","journal-title":"JAMA Oncology"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy","volume":"350","year":"2015","journal-title":"Science"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-3083.1989.tb01225.x","article-title":"The IgG subclass pattern of complement activation depends on epitope density and antibody and complement concentration","volume":"30","year":"1989","journal-title":"Scandinavian Journal of Immunology"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/pbc.25508","article-title":"Tumor-targeted and immune-targeted monoclonal antibodies: going from passive to active immunotherapy","volume":"62","year":"2015","journal-title":"Pediatric Blood and Cancer"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","year":"2017","journal-title":"Cancer Treatment Reviews"},{"key":"ref1631","first-page":"16-0108","article-title":"Hyponatraemia secondary to nivolumab-induced primary adrenal failure","volume":"2016","year":"2016","journal-title":"Endocrinology, Diabetes and Metabolism Case Reports"},{"key":"ref1251","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ando.2018.07.007","article-title":"Expert opinion on thyroid complications in immunotherapy","volume":"79","year":"2018","journal-title":"Annales d\u2019Endocrinologie"},{"key":"ref1361","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/S1470-2045(17)30428-X","article-title":"Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial","volume":"18","year":"2017","journal-title":"Lancet Oncology"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ando.2018.07.005","article-title":"Endocrine side-effects of new anticancer therapies: overall monitoring and conclusions","volume":"79","year":"2018","journal-title":"Annales d\u2019Endocrinologie"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1084\/jem.20051776","article-title":"Tissue expression of PD-L1 mediates peripheral T cell tolerance","volume":"203","year":"2006","journal-title":"Journal of Experimental Medicine"},{"key":"ref991","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ando.2017.10.007","article-title":"Group 4: replacement therapy for adrenal insufficiency","volume":"78","year":"2017","journal-title":"Annales d\u2019Endocrinologie"},{"key":"ref1411","doi-asserted-by":"crossref","first-page":"76565","DOI":"10.18632\/oncotarget.12088","article-title":"Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors","volume":"7","year":"2016","journal-title":"Oncotarget"},{"key":"ref1061","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab","volume":"101","year":"2016","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3109\/01676830.2014.949792","article-title":"Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab","volume":"33","year":"2014","journal-title":"Orbit"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1016\/j.molimm.2008.05.014","article-title":"Interaction of human PD-L1 and B7-1","volume":"45","year":"2008","journal-title":"Molecular Immunology"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","year":"2016","journal-title":"Lancet Oncology"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2213-8587(13)70031-7","article-title":"Ipilimumab-induced autoimmune adrenalitis","volume":"1","year":"2013","journal-title":"Lancet Diabetes and Endocrinology"},{"key":"ref1641","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","year":"2015","journal-title":"Science"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/S1470-2045(17)30428-X","article-title":"Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial","volume":"18","year":"2017","journal-title":"Lancet Oncology"},{"key":"ref841","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000485742","article-title":"Severe inflammatory ophthalmopathy in a euthyroid patient during nivolumab treatment","volume":"7","year":"2018","journal-title":"European Thyroid Journal"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms","volume":"102","year":"2017","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1141","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1470-2045(17)30240-1","article-title":"Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial","volume":"18","year":"2017","journal-title":"Lancet Oncology"},{"key":"ref1301","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","year":"2017","journal-title":"Frontiers in Pharmacology"},{"key":"ref1171","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"ref1331","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1055\/s-0033-1355337","article-title":"Hypophysitis caused by ipilimumab in cancer patients: hormone replacement or immunosuppressive therapy","volume":"121","year":"2013","journal-title":"Experimental and Clinical Endocrinology and Diabetes"},{"key":"ref1591","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ando.2018.07.006","article-title":"Expert opinion on immunotherapy induced diabetes","volume":"79","year":"2018","journal-title":"Annales d\u2019Endocrinologie"},{"key":"ref1271","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review","volume":"85","year":"2016","journal-title":"Clinical Endocrinology"},{"key":"ref1231","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2005.01.001","article-title":"Immunogenicity of engineered antibodies","volume":"36","year":"2005","journal-title":"Methods"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","article-title":"Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses","volume":"113","year":"2009","journal-title":"Blood"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1470-2045(17)30240-1","article-title":"Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial","volume":"18","year":"2017","journal-title":"Lancet Oncology"},{"key":"ref831","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-14-0845","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma","volume":"172","year":"2015","journal-title":"European Journal of Endocrinology"},{"key":"ref1191","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2018.04.001","article-title":"Immunotherapy-induced Addison\u2019s disease: a rare, persistent and potentially lethal side-effect","volume":"97","year":"2018","journal-title":"European Journal of Cancer"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1600-065X.2011.01011.x","article-title":"Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28\/\u200aB7 family","volume":"241","year":"2011","journal-title":"Immunological Reviews"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes","volume":"13","year":"2010","journal-title":"Pituitary"},{"key":"ref1491","first-page":"1165","article-title":"Adverse events associated with immune checkpoint blockade","volume":"378","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","year":"2014","journal-title":"Endocrine-Related Cancer"},{"key":"ref941","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1016\/j.molimm.2008.05.014","article-title":"Interaction of human PD-L1 and B7-1","volume":"45","year":"2008","journal-title":"Molecular Immunology"},{"key":"ref1011","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.autrev.2008.04.016","article-title":"Pituitary autoimmunity: 30 years later","volume":"7","year":"2008","journal-title":"Autoimmunity Reviews"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","year":"2016","journal-title":"Pituitary"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1097\/RLU.0000000000000887","article-title":"induced adrenalitis a possible pitfall in PET https org","volume":"18","author":"Ipilimumab","journal-title":"Clinical Nuclear Medicine"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1210\/js.2017-00170","article-title":"Polyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma","volume":"1","year":"2017","journal-title":"Journal of the Endocrine Society"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10637-009-9376-8","article-title":"A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-na\u00efve patients with advanced melanoma","volume":"29","year":"2011","journal-title":"Investigational New Drugs"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study","volume":"21","year":"2015","journal-title":"Clinical Cancer Research"},{"key":"ref791","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1200\/JCO.2008.16.1927","article-title":"Phase I\/II study of ipilimumab for patients with metastatic melanoma","volume":"26","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ando.2018.07.006","article-title":"Expert opinion on immunotherapy induced diabetes","volume":"79","year":"2018","journal-title":"Annales d\u2019Endocrinologie"},{"key":"ref1501","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","year":"2015","journal-title":"New England Journal of Medicine"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/26\/2\/ERC-18-0320.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/26\/2\/ERC-18-0320.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:55:04Z","timestamp":1784555704000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/erc\/article\/26\/2\/G1-G18\/25361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":172,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.1530\/erc-18-0320","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}